Drug class
Mannan-binding lectin-associated serine protease 2 (MASP-2) inhibitor; complement pathway monoclonal antibody
Mechanism of action
Inhibits MASP-2, the effector enzyme of the lectin pathway of complement, blocking lectin-dependent activation of complement components C3 and C4 without inhibiting the classical or alternative complement pathways.
General use cases
- Treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA) in adults and paediatric patients aged 2 years and older under the US YARTEMLEA indication (approved 23 December 2025)
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
